Michael Böhm

172.6k total citations · 25 hit papers
1.1k papers, 61.6k citations indexed

About

Michael Böhm is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Michael Böhm has authored 1.1k papers receiving a total of 61.6k indexed citations (citations by other indexed papers that have themselves been cited), including 785 papers in Cardiology and Cardiovascular Medicine, 241 papers in Surgery and 167 papers in Molecular Biology. Recurrent topics in Michael Böhm's work include Blood Pressure and Hypertension Studies (261 papers), Heart Failure Treatment and Management (228 papers) and Heart Rate Variability and Autonomic Control (159 papers). Michael Böhm is often cited by papers focused on Blood Pressure and Hypertension Studies (261 papers), Heart Failure Treatment and Management (228 papers) and Heart Rate Variability and Autonomic Control (159 papers). Michael Böhm collaborates with scholars based in Germany, United States and United Kingdom. Michael Böhm's co-authors include Ulrich Laufs, Georg Nickenig, Felix Mahfoud, Luigi Tavazzi, Michel Komajda, Jeffrey Borer, Karl Swedberg, Christian Ukena, Andreas Link and Erland Erdmann and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Michael Böhm

1.1k papers receiving 59.8k citations

Hit Papers

Ivabradine and outcomes in chronic heart ... 1993 2026 2004 2015 2010 2012 2005 2005 2021 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
    2010 1.7k citations Karl Swedberg, Michel Komajda et al. profile →
  2. Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock
    2012 1.6k citations Michael Böhm et al. profile →
  3. Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes
    2005 1.6k citations Michael Böhm, Georg Nickenig et al. profile →
  4. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
    2005 1.1k citations Dirk J. van Veldhuisen, Alain Cohen‐Solal et al. profile →
  5. Cardiovascular Disease in Chronic Kidney Disease
    2021 1.1k citations Michael Böhm et al. Circulation profile →
  6. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
    2010 822 citations Michael Böhm, Karl Swedberg et al. profile →
  7. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart.
    1993 707 citations Michael Böhm et al. Circulation profile →
  8. Physical Training Increases Endothelial Progenitor Cells, Inhibits Neointima Formation, and Enhances Angiogenesis
    2003 666 citations Ulrich Laufs, Sven Waßmann et al. Circulation profile →
  9. Update on Myocarditis
    2012 614 citations Ingrid Kindermann, Felix Mahfoud et al. profile →
  10. Intravenous Transfusion of Endothelial Progenitor Cells Reduces Neointima Formation After Vascular Injury
    2003 594 citations Ulrich Laufs, Michael Böhm et al. profile →
  11. Cardiovascular remodelling in coronary artery disease and heart failure
    2014 571 citations Michael Böhm et al. profile →
  12. Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter
    2006 557 citations Michael Böhm et al. profile →
  13. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial
    2013 551 citations Michael Böhm et al. profile →
  14. Impact of Remote Telemedical Management on Mortality and Hospitalizations in Ambulatory Patients With Chronic Heart Failure
    2011 513 citations Friedrich Koehler, Sebastian Winkler et al. Circulation profile →
  15. Predictors of Outcome in Patients With Suspected Myocarditis
    2008 450 citations Ingrid Kindermann, Michael Kindermann et al. Circulation profile →
  16. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
    2010 448 citations Michael Böhm et al. profile →
  17. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study
    2013 429 citations Henry Krum, Markus P. Schlaich et al. profile →
  18. Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension
    2011 399 citations Felix Mahfoud, Markus P. Schlaich et al. Circulation profile →
  19. Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension
    2012 372 citations Felix Mahfoud, Michael Böhm et al. profile →
  20. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
    2017 302 citations Dirk J. van Veldhuisen, Piotr Ponikowski et al. Circulation profile →
  21. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
    2016 299 citations Gerasimos Filippatos, Stefan D. Anker et al. profile →
  22. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
    2020 243 citations Stefan D. Anker, Gerasimos Filippatos et al. Circulation profile →
  23. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial
    2022 168 citations Felix Mahfoud, Roland E. Schmieder et al. profile →
  24. Hypertension management in patients with cardiovascular comorbidities
    2022 91 citations Felix Mahfoud, Markus P. Schlaich et al. profile →
  25. Interventional therapies for pulmonary embolism
    2023 53 citations Michael Böhm, Felix Mahfoud et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Böhm Germany 119 37.8k 14.1k 11.9k 7.2k 6.2k 1.1k 61.6k
Milton Packer United States 109 52.9k 1.4× 9.4k 0.7× 7.3k 0.6× 10.6k 1.5× 8.5k 1.4× 655 65.6k
Dirk J. van Veldhuisen Netherlands 126 43.8k 1.2× 7.9k 0.6× 5.7k 0.5× 5.6k 0.8× 7.7k 1.2× 857 60.8k
Thomas F. Lüscher Switzerland 127 28.1k 0.7× 13.6k 1.0× 11.6k 1.0× 6.6k 0.9× 6.3k 1.0× 1.1k 62.6k
Martin G. Larson United States 142 53.4k 1.4× 12.7k 0.9× 10.0k 0.8× 9.6k 1.3× 8.0k 1.3× 587 89.4k
Stefan D. Anker Germany 117 27.4k 0.7× 7.4k 0.5× 9.2k 0.8× 8.9k 1.2× 7.5k 1.2× 734 56.7k
Andrew J.S. Coats United Kingdom 106 40.4k 1.1× 7.2k 0.5× 5.2k 0.4× 4.3k 0.6× 6.4k 1.0× 660 54.4k
Faı̈ez Zannad France 102 38.6k 1.0× 10.2k 0.7× 7.7k 0.6× 19.2k 2.7× 11.6k 1.9× 958 57.7k
Lars Køber Denmark 110 39.2k 1.0× 10.5k 0.7× 6.0k 0.5× 10.1k 1.4× 5.6k 0.9× 1.4k 59.4k
Christodoulos Stefanadis Greece 96 21.2k 0.6× 7.7k 0.5× 4.8k 0.4× 5.2k 0.7× 5.7k 0.9× 1.3k 46.4k
Amir Lerman United States 107 27.2k 0.7× 15.0k 1.1× 8.0k 0.7× 3.0k 0.4× 8.3k 1.3× 881 51.0k

Countries citing papers authored by Michael Böhm

Since Specialization
Citations

This map shows the geographic impact of Michael Böhm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Böhm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Böhm more than expected).

Fields of papers citing papers by Michael Böhm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Böhm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Böhm. The network helps show where Michael Böhm may publish in the future.

Co-authorship network of co-authors of Michael Böhm

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Böhm. A scholar is included among the top collaborators of Michael Böhm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Böhm. Michael Böhm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wintrich, Jan, et al.. (2024). Latest pharmaceutical approaches across the spectrum of heart failure. Heart Failure Reviews. 29(3). 675–687. 3 indexed citations
2.
Wintrich, Jan, Johannes Brachmann, Ralph Bosch, et al.. (2023). Impedance-Based Remote Monitoring in Patients with Heart Failure and Concomitant Chronic Kidney Disease. ESC Heart Failure. 10(5). 3011–3018. 3 indexed citations
3.
Veldhuisen, Dirk J. van, Piotr Ponikowski, Peter van der Meer, et al.. (2017). Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation. 136(15). 1374–1383. 302 indexed citations breakdown →
4.
Greene, Stephen J., Aldo P. Maggioni, Gregg C. Fonarow, et al.. (2015). Clinical Profile and Prognostic Significance of Natriuretic Peptide Trajectory Following Hospitalization for Worsening Chronic Heart Failure: Findings from the ASTRONAUT Trial. European Journal of Heart Failure. 17(1). 98–108. 28 indexed citations
5.
Greene, Stephen J., Gregg C. Fonarow, Scott Solomon, et al.. (2015). Global Variation in Clinical Profile, Management, and Post-Discharge Outcomes Among Patients Hospitalized For Worsening Chronic Heart Failure: Findings from the ASTRONAUT trial. European Journal of Heart Failure. 17(6). 591–600. 47 indexed citations
6.
Böhm, Michael, Janice Pogue, Ingrid Kindermann, et al.. (2014). Effect of Comorbidities on Outcomes and Angiotensin Converting Enzyme Inhibitor Effects in Patients with Predominantly Left Ventricular Dysfunction and Heart Failure. European Journal of Heart Failure. 16(3). 325–333. 17 indexed citations
7.
Komajda, Michel, Michael Böhm, Jeffrey Borer, et al.. (2014). Efficacy and Safety of Ivabradine in Patients with Chronic Systolic Heart Failure According to Blood Pressure Level in SHIFT. European Journal of Heart Failure. 16(7). 810–816. 53 indexed citations
8.
Voors, Adriaan A., Dirk J. van Veldhuisen, Michele Robertson, et al.. (2014). The Effect of Heart Rate Reduction with Ivabradine on Renal Function in Patients with Chronic Heart Failure: An Analysis from SHIFT. European Journal of Heart Failure. 16(4). 426–434. 43 indexed citations
9.
Abrahamsson, Putte, Karl Swedberg, Jeffrey Borer, et al.. (2013). Risk Following Hospitalization in Stable Chronic Systolic Heart Failure. European Journal of Heart Failure. 15(8). 885–891. 35 indexed citations
10.
Tavazzi, Luigi, Karl Swedberg, Michel Komajda, et al.. (2013). Efficacy and Safety of Ivabradine in Chronic Heart Failure Across the Age Spectrum: Insights from the SHIFT Study. European Journal of Heart Failure. 15(11). 1296–1303. 60 indexed citations
11.
Reil, Jan‐Christian, Michele Robertson, Ian Ford, et al.. (2013). Impact of Left Bundle Branch Block on Heart Rate and its Relationship to Treatment with Ivabradine in Chronic Heart Failure. European Journal of Heart Failure. 15(9). 1044–1052. 23 indexed citations
12.
Esler, Murray, Henry Krum, Markus P. Schlaich, et al.. (2012). Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. Circulation. 126(25). 2976–2982. 325 indexed citations
13.
Koehler, Friedrich, Sebastian Winkler, Michael Schieber, et al.. (2011). Impact of Remote Telemedical Management on Mortality and Hospitalizations in Ambulatory Patients With Chronic Heart Failure. Circulation. 123(17). 1873–1880. 513 indexed citations breakdown →
14.
Conraads, Viviane M., Marco Metra, Otto Kamp, et al.. (2011). Effects of the Long-Term Administration of Nebivolol on the Clinical Symptoms, Exercise Capacity, and Left Ventricular Function of Patients with Diastolic Dysfunction: Results of the ELANDD Study. European Journal of Heart Failure. 14(2). 219–225. 160 indexed citations
15.
Koehler, Friedrich, Sebastian Winkler, Michael Schieber, et al.. (2010). Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a Randomized, Controlled Intervention Trial Investigating the Impact of Telemedicine on Mortality in Ambulatory Patients with Heart Failure: Study Design. European Journal of Heart Failure. 12(12). 1354–1362. 146 indexed citations
16.
Kohlhaas, Michael, Ting Liu, Andreas Knopp, et al.. (2010). Elevated Cytosolic Na + Increases Mitochondrial Formation of Reactive Oxygen Species in Failing Cardiac Myocytes. Circulation. 121(14). 1606–1613. 259 indexed citations
17.
Böhm, Michael, Magnus Baumhäkel, Koon Teo, et al.. (2010). Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both. Circulation. 121(12). 1439–1446. 132 indexed citations
18.
Luca, Leonardo De, Alexandre Mebazaa, Gerasimos Filippatos, et al.. (2008). Overview of Emerging Pharmacologic Agents for Acute Heart Failure Syndromes. European Journal of Heart Failure. 10(2). 201–213. 31 indexed citations
19.
Kindermann, Ingrid, Michael Kindermann, Reinhard Kandolf, et al.. (2008). Predictors of Outcome in Patients With Suspected Myocarditis. Circulation. 118(6). 639–648. 450 indexed citations breakdown →
20.
Laufs, Ulrich, Sven Waßmann, Thomas Czech, et al.. (2005). Physical Inactivity Increases Oxidative Stress, Endothelial Dysfunction, and Atherosclerosis. Arteriosclerosis Thrombosis and Vascular Biology. 25(4). 809–814. 234 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Milton Packer Breakdown of academic impact, for papers by Dirk J. van Veldhuisen Breakdown of academic impact, for papers by Thomas F. Lüscher Breakdown of academic impact, for papers by Martin G. Larson Breakdown of academic impact, for papers by Stefan D. Anker Breakdown of academic impact, for papers by Andrew J.S. Coats Breakdown of academic impact, for papers by Faı̈ez Zannad Breakdown of academic impact, for papers by Lars Køber Breakdown of academic impact, for papers by Christodoulos Stefanadis Breakdown of academic impact, for papers by Amir Lerman
Rankless by CCL
2026